Prevail Therapeutics nets $116.3mm in IPO
Neurodegenerative-focused Prevail Therapeutics Inc. (adeno-associated virus (AAV)-based vectors for gene therapies) netted $116.3mm in its initial public offering of 7.4mm shares at $17, the midpoint of its anticipated range.
- Site Specific
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com